很高兴和大家分享，临床肿瘤科专科张文龙医生早前于 Best of ASCO 2025, Hong Kong 担任肺癌及泌尿科肿瘤环节（Lung and Urological Cancers Session）的主持人，带领国际专家和医疗专业人士深入探讨肺癌治疗的最新研究成果与未来发展方向。

Best of ASCO 2025, HONG KONG 是由美国临床肿瘤学会（ASCO）与香港国际肿瘤临床研究学会（HKIORS）联合举办的年度学术盛事，已于7月5日圆满落幕。活动将 2025 年全球最新、最具突破性的肿瘤学研究成果带到香港，帮助本地及亚太地区的医疗专业人士掌握癌症治疗的新趋势与临床进展。

在张医生主持的肺癌专场中，邀请了国际知名学者 Prof. Shun Lu 及 Prof. Patrick Forde。他们分享了关于非小细胞肺癌治疗的最新研究成果，与会者围绕肺癌治疗领域的最新临床进展展开了深入讨论。这些突破性研究不仅为提升患者治疗效果带来了新希望，也对临床实践产生了深远影响。

It is with great pleasure that I share Dr. Teo Man Lung recently presided over the Lung and Urological Cancers Session at Best of ASCO 2025, Hong Kong. He led a panel of international experts and medical professionals in a thorough discussion on the latest research findings and future directions in lung cancer treatment.

Best of ASCO 2025, Hong Kong, a joint annual academic event formally licensed by the American Society of Clinical Oncology (ASCO), in collaboration with the Hong Kong International Oncology Clinical Research Society (HKIORS), concluded successfully on July 5th. The event brought the latest and most groundbreaking oncological research of 2025 to Hong Kong, aiding local and Asia-Pacific medical professionals in keeping abreast of new trends and clinical advancements in cancer treatment.

The lung cancer segment featured renowned scholars, Prof. Shun Lu and Prof. Patrick Forde, who shared their latest research on the treatment of non-small cell lung cancer. The discussions were deep and focused on recent clinical advancements in the field of lung cancer treatment. These groundbreaking studies not only bring new hope for improving patient treatment outcomes but also have a profound impact on clinical practices.